Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00135941
First received: August 23, 2005
Last updated: June 2, 2009
Last verified: June 2009
  Purpose

The purpose of this study is to test for superiority in improvements from baseline in patient reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin glargine plus rapid acting insulin glulisine MDI versus treatment with premix insulin.


Condition Intervention Phase
Diabetes Mellitus
Drug: insulin glargine
Drug: insulin glulisine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Evaluating Differences in Patient Reported Outcomes

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • To compare improvements from baseline in patient reported outcomes (quality of life, treatment satisfaction) when aggressively treated with insulin glargine plus rapid acting insulin glulisine vs treatment with Premix insulin [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • change in A1c (baseline to week 24), reported hypo events (throughout the trials), correlation between patient reported outcomes and glucose variability as measured by CGMS (baseline, week 8 and week 20). [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 582
Study Start Date: August 2005
Study Completion Date: September 2007
Arms Assigned Interventions
Experimental: 1
Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
Drug: insulin glargine
Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
Experimental: 2
Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
Drug: insulin glulisine
Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.

  Eligibility

Ages Eligible for Study:   21 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent in writing at enrollment
  • Subjects with type 1 or type 2 diabetes mellitus for at least six months
  • Male or female 21 - 70 years of age
  • Employed, unpaid work or active lifestyle
  • Screening hemoglobin A1c (HbA1c) level of ≥ 7.0 and ≤ 9.0 %
  • Current (last 3 months) daily use of premix insulin 75/25, 70/30, or isophane insulin (NPH) or Lantus with short acting insulin, consisting of 2 or more injections per day with or without concomitant therapy consisting of metformin, thiazolidinedione, and/or alpha-glucosidase inhibitors.
  • Willing and able to inject insulin glargine and multi-day dosing of insulin glulisine.
  • Willing and able to perform self-monitoring of blood glucose (SMBG) four times a day and continuous glucose monitoring (CGMS) for 48 hours at three time periods during the study
  • Willing and able to use adequate contraception if of child bearing age
  • Able to read and understand English (at the sixth grade level) and comply with the study protocol

Exclusion Criteria:

  • Cardiac status New York Heart Association (NYHA) III-IV
  • Serum creatinine ≥ 1.5 mg/dl for males, or ≥ 1.4 mg/dl for females.
  • Clinical evidence of active liver disease or serum ALT or AST > 2.5 times the upper limit of normal range.
  • Subjects currently using an insulin pump
  • Subjects currently taking sulfonylureas, repaglinide, nateglinide, symlin (pramlintide acetate) or byetta (exenatide).
  • Planned pregnancy in next 6 months or pregnant or lactating females
  • Diagnosis of dementia or mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study
  • Unable to obtain complete CGMS data prior to baseline, visit 2 (week 0)
  • Hypersensitivity to insulin glargine or insulin glulisine or premix insulin or any of their components
  • Any disease or condition (including abuse of illicit drugs, prescription medicines or alcohol) that in the opinion of the investigator or sponsor may interfere with the study compliance and completion of the study.
  • Treatment with intermittent doses of systemic steroids or intermittent large doses of inhaled steroids for the past one year (treatment with fixed doses for the past 6 months is acceptable providing there is no plan to change the dosage regimen)
  • Treatment with any investigational product in the last 3 months before study entry
  • Stroke, myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA), or unstable angina pectoris within the last 12 months
  • Current malignancy, any previous breast cancer, any previous malignant melanoma or any cancer within the past 5 years (except adequately treated basal cell skin cancer)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00135941

Locations
United States, Wisconsin
Advanced Healthcare
Milwaukee, Wisconsin, United States, 53209
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Lisa Jean-Louis Sanofi
  More Information

No publications provided by Sanofi

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00135941     History of Changes
Other Study ID Numbers: HMR1964A_3508
Study First Received: August 23, 2005
Last Updated: June 2, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Sanofi:
Diabetes Mellitus, Type 2

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Glargine
Insulin glulisine
Insulin
Insulin, Long-Acting
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 18, 2014